Adjuvant chemotherapy omission after pancreatic cancer resection: a French nationwide study
World Journal of Surgical Oncology · 06.05.2024 · 22 (1)
DOI: 10.1186/s12957-024-03393-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Surgical Oncology, online erschienen am 06.05.2024. Verfasst von Charles Poiraud und 7 weiteren Autor:innen. Beteiligte Einrichtung: Digestive Surgery and Transplantation Department, CHU de Lille, 59000, Lille, France. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Pancreatectomy. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Adjuvant chemotherapy (AC) improves the prognosis after pancreatic ductal adenocarcinoma (PDAC) resection. However, previous studies have shown that a large proportion of patients do not receive or complete AC. This national study examined the risk factors for the omission or interruption of AC.
Methods
Data of all patients who underwent pancreatic surgery for PDAC in France between January 2012 and December 2017 were extracted from the French National Administrative Database. We considered “omission of adjuvant chemotherapy” (OAC) all patients who failed to receive any course of gemcitabine within 12 postoperative weeks and “interruption of AC” (IAC) was defined as less than 18 courses of AC.
Results
A total of 11 599 patients were included in this study. Pancreaticoduodenectomy was the most common procedure (76.3%), and 31% of the patients experienced major postoperative complications. OACs and IACs affected 42% and 68% of the patients, respectively. Ultimately, only 18.6% of the cohort completed AC. Patients who underwent surgery in a high-volume centers were less affected by postoperative complications, with no impact on the likelihood of receiving AC. Multivariate analysis showed that age ≥ 80 years, Charlson comorbidity index (CCI) ≥ 4, and major complications were associated with OAC (OR = 2.19; CI 95% [1.79–2.68]; OR = 1.75; CI 95% [1.41–2.18] and OR = 2.37; CI 95% [2.15–2.62] respectively). Moreover, age ≥ 80 years and CCI 2–3 or ≥ 4 were also independent risk factors for IAC (OR = 1.54, CI 95% [1.1–2.15]; OR = 1.43, CI 95% [1.21–1.68]; OR = 1.47, CI 95% [1.02–2.12], respectively).
Conclusion
Sequence surgery followed by chemotherapy is associated with a high dropout rate, especially in octogenarian and comorbid patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Digestive Surgery and Transplantation Department, CHU de Lille, 59000, Lille, France.
- University of Lille, 59000, Lille, France.
- Department of Medical Information, CHRU de Lille, 59000, Lille, France.
- Medical Oncology Department, CHU de Lille, 59000, Lille, France.
- Digestive Surgery and Transplantation Department, CHU de Lille, 59000, Lille, France. mehdi_elamrani@hotmail.fr.
- University of Lille, 59000, Lille, France. mehdi_elamrani@hotmail.fr.
Zitieren
APA
Poiraud, C., Lenne, X., Bruandet, A., Theis, D., Bertrand, N., Turpin, A., Truant, S., & El Amrani, M. (2024). Adjuvant chemotherapy omission after pancreatic cancer resection: a French nationwide study. World Journal of Surgical Oncology, 22(1). https://doi.org/10.1186/s12957-024-03393-7
Vancouver
Poiraud C, Lenne X, Bruandet A, Theis D, Bertrand N, Turpin A, et al. Adjuvant chemotherapy omission after pancreatic cancer resection: a French nationwide study. World Journal of Surgical Oncology. 2024;22(1). doi:10.1186/s12957-024-03393-7
BibTeX
@article{Poiraud2024,
author = {Poiraud, Charles and Lenne, Xavier and Bruandet, Amélie and Theis, Didier and Bertrand, Nicolas and Turpin, Anthony and Truant, Stephanie and El Amrani, Mehdi},
title = {Adjuvant chemotherapy omission after pancreatic cancer resection: a French nationwide study},
journal = {World Journal of Surgical Oncology},
year = {2024},
volume = {22},
number = {1},
doi = {10.1186/s12957-024-03393-7}
}
EUVIMED